Long-Term Use of Tralokinumab in Patients With Atopic Dermatitis: A Real-World Multicentric Case Series

Affiliations

¹ Department of Dermatology, Medical University of Vienna, Vienna, Austria.
² Department of Dermatology and Venereology, Elisabethinen Hospital, Linz, Austria.
³ Department of Dermatology and Venereology, Klinikum Wels-Grieskirchen, Wels, Austria.
⁴ Department of Dermatology and Allergology, University Hospital Salzburg of the Paracelsus Medical University, Salzburg, Austria.
⁵ Department of Dermatology and Venereology, Kepler University Hospital, Linz, Austria.

Christine Bangert et al. Int J Dermatol. 2025.

. 2025 Jun 17.

doi: 10.1111/ijd.17913. Online ahead of print.

¹ Department of Dermatology, Medical University of Vienna, Vienna, Austria.
² Department of Dermatology and Venereology, Elisabethinen Hospital, Linz, Austria.
³ Department of Dermatology and Venereology, Klinikum Wels-Grieskirchen, Wels, Austria.
⁴ Department of Dermatology and Allergology, University Hospital Salzburg of the Paracelsus Medical University, Salzburg, Austria.
⁵ Department of Dermatology and Venereology, Kepler University Hospital, Linz, Austria.

No abstract available

Keywords: atopic dermatitis; case series; long‐term effectiveness; long‐term safety; real‐world evidence; tralokinumab.

References

1. A. De Greef, P. D. Ghislain, A. Bulinckx, et al., “Real‐Life Experience of Tralokinumab for the Treatment of Adult Patients With Severe Atopic Dermatitis: A Multicentric Prospective Study,” Clinical Drug Investigation 43, no. 4 (2023): 299–306.
1. J. J. Pereyra‐Rodriguez, P. Herranz, R. Ruiz‐Villaverde, et al., “Treatment of Severe Atopic Dermatitis With Tralokinumab in Clinical Practice: Short‐Term Effectiveness and Safety Results,” Clinical and Experimental Dermatology 48, no. 9 (2023): 991–997.
1. S. Ferrucci, F. Barei, S. Tavecchio, et al., “Assessment of Patient‐Reported Outcomes at 24 Weeks of Treatment With Tralokinumab for Atopic Dermatitis: A Multicentric Real‐Life Experience,” Journal of Dermatological Treatment 34, no. 1 (2023): 2285243.
1. E. Pezzolo, D. Schena, A. Gambardella, et al., “Survival, Efficacy and Safety of Tralokinumab After 32 and 52 Weeks of Treatment for Moderate‐To‐Severe Atopic Dermatitis in Adults: A Multicentre Real‐World Study,” Journal of the European Academy of Dermatology and Venereology 38, no. 1 (2024): e11–e13.
1. A. Blauvelt, R. G. Langley, K. Peris, et al., “551—Continuous Tralokinumab Treatment Over 4 Years in Adults With Moderate‐To‐Severe Atopic Dermatitis Provides Long‐Term Disease Control,” British Journal of Dermatology 190, no. Supplement_2 (2024): ii48–ii49.